Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis
Main Article Content
Keywords
Actinic Keratosis, Ingenol Mebutate, topical, Local skin reaction, management
Abstract
References
2. Bettencourt MS. Tolerability of ingenol mebutate gel, 0.05%, for treating patients with actinic keratosis on the scalp in a community dermatology practice. J Clin Aesthet Dermatol. 2016;9(3):20-24.
3. Picato (ingenol mebutate) gel 0.015%, 0.05% [package insert]. Madison, NJ: LEO Pharma Inc.; 2019.
4. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.
5. Hanke WC, Norlin JM, Mark Knudsen K, et al. Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016;27(5):450-455.
6. Joe HJ, Oh BH. Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients. Clin Cosmet Investig Dermatol. 2017;10:93-98.
7. Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014;13(3):269-273.
8. Erlendsson AM, Karmisholt KE, Haak CS, et al. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): a randomized clinical trial. J Am Acad Dermatol. 2016;74(4):709-715.
9. Jim On SC, Hashim PW, Nia JK, Lebwohl MG. Assessment of efficacy and irritation of ingenol mebutate gel 0.015% used with or without dimethicone lotion for treatment of actinic keratosis on the face. J Drugs Dermatol. 2017;16(5):432-436.
10. Neri L, Peris K, Longo C, et al; Actinic Keratosis — TReatment Adherence INitiative (AK-TRAIN) study group. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019;33(1):93-107.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.